1329-P: National Differences and Similarities in Youth-Onset Type 2 Diabetes
Authors: LYNCH JANE L. , BARRIENTOS-PÉREZ MARGARITA , HAFEZ MONA , JALALUDIN MUHAMMAD YAZID , KOVARENKO MARGARITA , PATURI VISHNUPRIYA RAO , WEGHUBER DANIEL ,   NOVO NORDISK PAEDIATRIC T2D GLOBAL EXPERT PANEL
Published: June 2019

Background: With the recent increased awareness of youth-onset type 2 diabetes (T2D) cases, an overview of national differences in epidemiology data is needed to obtain a global picture of the disease development.

Methods and Aim: This review examined national epidemiology data of youth-onset T2D published between 1st January 2008 and 15th January 2018, and searched for national guidelines on this topic to understand better national similarities and differences.

Results: Of the 1005 articles and 14 congress abstracts identified, 42 studies were included. The highest reported prevalence rates of youth-onset T2D were found in the U.S. and China (38 and 18 cases/100,000 people, respectively), and lowest in Denmark and Ireland (0.6 and 1.2 cases/100,000 people, respectively) (Figure). However, the highest incidence rates were reported in Taiwan and the UK (63 and 33 cases/100,000 people, respectively), with the lowest in Fiji and Austria (0.4 and 0.6 cases/100,000 people, respectively) (Figure). These differences may be partly explained by variations in diagnostic criteria, national screening recommendations, and ethnicity within countries.

Conclusions: Our review suggests that published national epidemiology data for youth-onset T2D may underestimate its disease burden. Finding optimal diagnostic criteria and screening strategies for this disease should be of high interest to every country.

Disclosure

J.L. Lynch: Board Member; Self; American Academy of Pediatrics. Consultant; Self; Novo Nordisk Inc. Research Support; Self; Daiichi Sankyo Company, Limited, National Institutes of Health, Novo Nordisk Inc., Pediatric Diabetes Consortium. M. Barrientos-Pérez: Advisory Panel; Self; Novo Nordisk A/S. Research Support; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; Pfizer Inc. M. Hafez: Advisory Panel; Self; Merck & Co., Inc. Consultant; Self; Global Expert Panel for T2 diabetes. M. Jalaludin: Advisory Panel; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. Research Support; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. M. Kovarenko: Advisory Panel; Self; Novo Nordisk Pediatric Type 2 Diabetes Global Expert Panel. Speaker's Bureau; Self; Berlin-Chemie AG, LifeScan, Inc., Medtronic, Novo Nordisk A/S, Sanofi. V. Paturi: Advisory Panel; Self; Novo Nordisk Foundation. Board Member; Spouse/Partner; DiabetOmics Inc., DiabetOmics Inc. Board Member; Self; DiabetOmics Medical. Consultant; Self; Ramdevrao Hospital. Employee; Self; DiabetOmics Medical. Research Support; Self; Eli Lilly and Company, Hetero Pharma, Ipca Laboratories Ltd., IQVIA, Novo Nordisk A/S, Quintiles, RSSDI (Research Society for the Study of Diabetes in India), Sanofi. Speaker's Bureau; Self; Novo Nordisk A/S. Stock/Shareholder; Self; DiabetOmics Inc. D. Weghuber: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Johnson & Johnson.

Funding

Novo Nordisk A/S